Zabeen Mahuwala, MD
Neurology · Lexington, KYNPI 1427336890
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,180 of the $27,803 with a category attached, or 69.0%. 28 manufacturers reported payments, led by AstraZeneca at 39.3% of the total. 2025 is the largest year on record at $13,947, 8.3 times the $1,675 reported in 2019.
Across 154 payments — averaging $180.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$11K
- Amgen$8K
- Johnson & Johnson$4K
- Janssen Scientific Affairs, LLC$1K
- UCB SA$1K
- UCB, Inc.$980
- plus $2K from 22 others
Across 58 payments — averaging $11,483 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$572K
- AstraZeneca$57K
- Argenx US, Inc.$37K
What the payments were for
- Consulting fees$19,18069%
- Speaking & faculty fees$1,5285%
- Travel & lodging$2,83010%
- Food & beverage$4,21815%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 21 | $10,926 |
| Amgen | 8 | $7,899 |
| Johnson & Johnson | 4 | $3,780 |
| Janssen Scientific Affairs, LLC | 3 | $1,287 |
| UCB SA | 8 | $1,127 |
| UCB, Inc. | 39 | $980 |
| CSL Behring | 19 | $404 |
| Neuropace, Inc. | 3 | $289 |
| Argenx US, Inc. | 4 | $164 |
| Eisai Inc. | 6 | $136 |
| Biohaven Pharmaceuticals, Inc. | 3 | $108 |
| Biogen | 4 | $101 |
| Genentech USA, Inc. | 1 | $73 |
| Teva Pharmaceuticals USA, Inc. | 4 | $69 |
| Akcea Therapeutics, Inc. | 4 | $69 |
| Neurelis, Inc. | 4 | $68 |
| Grifols USA, LLC | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Jazz Pharmaceuticals Inc. | 2 | $41 |
| Sunovion Pharmaceuticals Inc. | 3 | $29 |
| Catalyst Pharmaceuticals, Inc. | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
| Sarepta Therapeutics, Inc. | 1 | $16 |
| Novartis | 1 | $16 |
| AbbVie | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,803 in reported general payments places this provider in the 85th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RystiggoRozanolixizumab-Noli | 58 | $1,073,211 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 63 | $602,983 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 70 | $131,067 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 13 | $125,529 |
| BriviactBrivaracetam | 38 | $68,465 |
| AptiomEslicarbazepine Acetate | 17 | $28,137 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 20 | $15,609 |
| FycompaPerampanel | 11 | $12,928 |
| Mycophenolic AcidMycophenolate Sodium | 29 | $10,291 |
| MestinonPyridostigmine Bromide | 11 | $8,246 |
| Lacosamide | 46 | $7,977 |
| Pyridostigmine Bromide | 42 | $7,351 |
| Clobazam | 24 | $7,196 |
| Mycophenolate Mofetil | 53 | $6,899 |
| Levetiracetam | 67 | $3,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Rystiggo, Briviact | $980 | $1,141,67696 claims |
| CSL BehringHizentra | $404 | $602,98363 claims |
| Grifols USA, LLCGamunex-C | $68 | $131,06770 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $29 | $28,13717 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $15 | $14,25095 claims |
| Eisai Inc.Fycompa | $136 | $12,92811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 210 neurology providers in Kentucky.
Other neurology in Lexington
- James WinkleyLexington$807K
- Nicole EvermanLexington$355K
- Toufic FakhouryLexington$278K
- Fred OdagoLexington$28K
- Jagannadha AvasaralaLexington$15K
- Joshua ChalkleyLexington$15K
- Brian PlatoLouisville$232K
- Kristi NordLouisville$217K
- Naveed AhmedPikeville$215K
- Angela HardwickLouisville$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.